CYB 006
Alternative Names: CYB-006Latest Information Update: 13 Apr 2022
Price :
$50 *
At a glance
- Originator Adelia Therapeutics
- Developer Adelia Therapeutics; Cybin
- Class Behavioural disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Psychiatric disorders